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Abstract 
Hidradenitis suppurativa is a chronic, recurrent follicular occlusion disease with painful, 
sometimes debilitating, cutaneous draining lesions and subcutaneous abscesses (DynaMed Plus, 
2016). Hidradenitis suppurativa is understood to be a multifactorial disease that is hard to treat in 
some patients, especially those with a severe form of the disease. For this project, the efficacy of 
adalimumab for hidradenitis suppurativa was assessed and whether it is more beneficial than 
traditional treatments used. Adalimumab is a TNF-alpha inhibitor which belongs to the biologic 
DMARDs drug class. Kimball et al. (2012) found that at week 16 of their trial 3.9% of the 
placebo patients, 9.6% of every other week (EOW) dosing of adalimumab patients, and 17.6% of 
every week dosing of adalimumab patients achieved clinical response. Patient response reports 
on pain and outcomes were significantly greater in the weekly dosed patients vs. placebo group. 
A study by Miller et al. (2011) showed a significant reduction in Sartorious score after 6 weeks 
and an almost significant reduction seen after 12 weeks when compared to the placebo group (-
10.7 vs. 7.5, P=0.024 and -11.3 vs. 5.8, P=0.07). Kimball et al. (2016) showed clinical response 
rates at week 12 were significantly higher for the groups receiving adalimumab weekly than for 
the placebo groups: 41.8% versus 26.0% in PIONEER I (P=0.003) and 58.9% versus 27.6% in 
PIONEER II (P<0.001). DynaMed Plus, PubMed, and Cochran Library were searched with key 
words: hidradenitis suppurativa, adalimumab, and treatment. 
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Introduction 
Hidradenitis suppurativa, or acne inversa, is a recurring chronic inflammatory follicular 
occlusion that varies in severity from a few pimple-like lesions to deep painful abscesses and can 
be very debilitating to patients depending on the severity. Commonly a secondary bacterial 
infection will follow this inflammatory response. Hidradenitis suppurativa is seen in many 
different sites on the body. “The sites affected in the order of decreasing frequency include: 
axillary, inguinal, perineal, perianal, mammary and inframammary, buttocks, pubic region, chest, 
scalp, retroauricular, and eyelid” (Scuderi,2017, p. 96). This disorder has a prevalence of 1-4% 
worldwide and has a female to male ratio of 3:1 (DynaMed Plus, 2016). The disease has a peak 
onset in the early twenties and is rarely seen before puberty or after menopause (DynaMed Plus, 
2016). Using the Hurley Clinical Staging scale there are three stages to the disease: stage I is 
single or multiple abscess formation without sinus tracts and cicatrization, stage II is recurrent 
single of multiple widely separated lesions with tract formation and cicatrization, and stage III is 
multiple interconnecting tracts and abscesses across entire area with diffuse or near-diffuse 
involvement (DynaMed Plus, 2016). These stages are used to decide which treatment options 
would benefit the specific patient.  
The etiology of this disorder is not completely understood but it is likely multifactorial 
with some of the possible contributing factors including: genetics, hormones, and aberrant 
immune response that causes upregulated cytokines (DynaMed Plus, 2016). Risk factors include 
family history, smoking, obesity, mechanical friction, and certain medications (DynaMed Plus, 
2016).  Traditional treatments for this disorder consisted of antibiotics, hormone therapy, 
retinoids, corticosteroid injections, surgical intervention, pain management, and patient 
counselling on weight loss and smoking cessation. More recently, the tumor necrosis factor-
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alpha (TNF-alpha) inhibitor adalimumab was approved by the Food and Drug Administration 
(FDA) for treating hidradenitis suppurativa. Adalimumab (brand name Humira) is a member of 
the drug class biologic disease-modifying antirheumatic drugs (DMARDs), and this class is used 
often when treating rheumatic diseases. The use of TNF-alpha inhibitors for hidradenitis 
suppurativa was an accidental discovery. Patients with Crohn’s disease that also had hidradenitis 
suppurativa were being treated with adalimumab for the Crohn’s and there was improvement 
seen in the hidradenitis suppurativa lesions as well. Adalimumab is a recombinant human 
immunoglobulin G1 (IgG1) monoclonal antibody that binds to TNF-alpha and blocks its 
interaction with endogenous cell surface TNF receptors (DynaMed Plus, 2018). Other drugs of 
this class have been shown to have benefits when treating hidradenitis suppurativa however more 
studies are needed to be certain of their efficacy and adalimumab is still the only FDA approved 
TNF inhibitor for treatment of hidradenitis suppurativa. Adalimumab is only available in a 
subcutaneous injection; however different dosages are available depending on what is being 
treated. 
Statement of the Problem 
There is no cure for hidradenitis suppurativa and although there are many treatment 
options available, the traditional treatments do not provide adequate relief of symptoms for some 
patients. Adalimumab, though not a cure, may provide more beneficial treatment then these 
traditional options alone. This review was needed to evaluate research supporting the efficacy of 
adalimumab for hidradenitis suppurativa and to compare the risks and benefits of using this 
medication. 
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Research Questions 
In patients with hidradenitis suppurativa is adalimumab more effective than traditional 
treatments to include antibiotics, hormone therapy, retinoids, corticosteroid injections, surgical 
intervention, and pain management in treatment outcomes? 
In patients with hidradenitis suppurativa does adalimumab show better treatment 
outcomes in patients with severe disease vs mild or moderate disease? 
In patients with hidradenitis suppurativa are the side effect outcomes associated with 
adalimumab treatment more significant or detrimental than side effect outcomes associated with 
the traditional treatment options? 
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Review of the Literature 
My research methods included searching PubMed, Cochrane Library, and DynaMed Plus 
for clinical trials that had been done within the last ten years. Through a literature review I 
searched PubMed for randomized clinical trials that compared the use of adalimumab for 
hidradenitis suppurative against a placebo group using mesh headings “hidradenitis suppurative” 
and “adalimumab.” This produced three clinical trials that I used for my research done within the 
last ten years. I then searched the Cochrane Library database for a systematic review pertaining 
to adalimumab for hidradenitis suppurativa, this search did produce a review. The topics 
“adalimumab” and “hidradenitis suppurativa” were accessed on DynaMed Plus, and these topic 
pages gave me information on the background, etiology, and current treatment guidelines for 
hidradenitis suppurativa.  
Many of the studies had low patient numbers however there are two studies, PIONEER I 
and II, that had larger patient numbers and these patients were followed for a longer time period. 
Many of the peer review journal articles I have found reference the PIONEER studies and they 
are regarded as revolutionary studies for treatment of hidradenitis suppurativa.  
I then searched PubMed for clinical trials using the mesh headings “surgical treatment” 
and “hidradenitis suppurative”, this produced no studies assessing the efficacy of surgical 
treatment alone for hidradenitis suppurativa. A search of PubMed for clinical trials using the 
mesh terms “corticosteroids”, “steroids”, “treatment” and “hidradenitis suppurative” produced no 
studies. I then searched PubMed for clinical trials using the mesh headings “hormone”, 
“treatment”, and “hidradenitis suppurative” this produced one study which was only done using 
female subjects and did not have a placebo group and therefore was not used. With another 
search of PubMed I used mesh headings “anti-bacterial agents,” “antibiotic,” and “hidradenitis 
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suppurative” which produced one study comparing two antibiotics to each other but there was no 
placebo group and so this study was not used. A search was conducted on PubMed for clinical 
trials using the mesh headings “retinoids” and “hidradenitis suppurative” this search produced 
two studies however they were both older than ten years and had no placebo control group and 
were not used in this project.  
 As you can see by my searches there are not many studies available to show the 
effectiveness of other treatment options for hidradenitis suppurativa. This disease is not common 
so finding the patient numbers in a geographical region and having follow up would be difficult. 
For years this disease has been treated with the traditional treatment options mentioned above 
without many studies with data backing up their efficacy. With adalimumab for hidradenitis 
suppurativa there are several more studies available when compared to traditional treatments. 
However, it is understood that because this is a multifactorial disorder there may be several 
treatment options and sometimes multimodal treatment that could have some benefit. Much of 
the treatment for hidradenitis suppurativa is finding what works best for each individual patient. 
Theme One: Hidradenitis Suppurativa Etiology and Pathogenesis  
 As mentioned previously the etiology of hidradenitis suppurativa is not completely 
understood however it is thought to be a follicular occlusion. “The occlusion is caused by 
infundibular keratosis and hyperplasia of the follicular epithelium and results in accumulation of 
cellular debris, leading to cyst formation” (Prens, 2015). Prens et al. (2015) discuss how the 
follicular occlusion leads to dilation of the hair follicle followed by rupture of the debris into the 
surrounding dermis, and how this action causes an inflammatory response that attracts 
neutrophils, lymphocytes, and histiocytes. In this article by Prens et al. (2015) they also discuss 
how it is theorized that this response follicular occlusion is due to a deficiency in the follicular 
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skin immune system, whereas, another theory suggests that it is due to an overactive immune 
system that causes this inflammatory response to harmless bacteria. 
 When it was discovered that hidradenitis suppurativa responded to the TNF-alpha 
inhibitors researches started to dig deeper into the theory of an overactive immune system. Prens 
et al. (2015) discussed how some studies have shown TNF-alpha at the mRNA and protein levels 
in the hidradenitis suppurativa affected skin, and increased levels of IL-10 in this skin have also 
been reported. Other studies have demonstrated increased upregulation IL-1beta in hidradenitis 
lesions and perilesional skin (Prens, 2015). These findings are all suggestive towards the theory 
that an overactive immune system has a role in the pathophysiology and development of 
hidradenitis suppurativa. 
 Smoking and mechanical stress caused by obesity can also play a part in the development 
of hidradenitis suppurativa and its severity. When treating a patient with hidradenitis suppurativa 
they should be counselled on smoking cessation and weight loss, this may require referrals for a 
dietician. Woodruff et al (2015) state that 35% to 40% of patients with hidradenitis suppurativa 
report a family history. Lee et al. (2017) mentions in their article that hidradenitis suppurative is 
associated with multiple comorbidities, such as: obesity, metabolic syndrome, inflammatory 
bowel disease, and spondyloarthropathy. This is particularly interesting as spondyloarthropathy 
can also be treated with TNF- alpha inhibitors and inflammatory bowel disease is common in 
rheumatological diseases. I learned this during my rheumatology rotation whilst enrolled in the 
UND PA Program. 
 Hidradenitis can vary in severity from mild to moderate to severe. It can also be classified 
into one of three stages using the Hurley staging scale, other scales such as Sartorius scale, HS-
Physician’s Global Assessment, Hidradenitis Suppurativa Clinical Response, and Hidradenitis 
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Suppurativa Severity Scale are also used although are not as prominent as the Hurley staging 
scale in clinical trials. In an article from the Journal of the American Academy of Dermatology 
written by van der Zee et al. (2015) describes the different clinical presentations of hidradenitis 
suppurativa to include: regular type, frictional furuncle type, scarring folliculitis type, conglobate 
type, syndromic type, and ectopic type. The authors of this article point out how there is not 
much data supporting these different presentation types however in the future they could be 
important in determining treatment options as certain presentation types may respond better to 
different types of treatment.  
 Early diagnosis and aggressive treatment is important because once the disease has 
advanced and causing destruction of the cutaneous architecture it becomes more difficult to 
handle. (Woodruff, 2015). Woodruff et al. (2015) also point out that the advanced disease is 
associated with debilitating medical and psychosocial outcomes. “Diffuse fibrosis and scarring, 
especially with axillary disease, can lead to limb contractures and impaired mobility.” 
(Woodruff, 2015, p.1680). Shanmugam et al. (2017) discuss in their review article that 
hidradenitis suppurativa, like other chronic inflammatory diseases, is associated with a 
significantly increased risk of cardiovascular disease. “The increased risk of cardiovascular 
disease may be explained by uncontrolled inflammation” (Shanmugam, 2017, p.3). The 
diagnosis of hidradenitis is done clinically, there are no diagnostic tests required for diagnosis. 
Ball et al. (2016) do point out the need to swab any discharge from the abscesses to rule out 
infection and colonization.  Lee et al. (2017) discuss the psychosocial effects of hidradenitis 
suppurativa, the pain, malodorous discharge, and scarring can lead to impairment of quality of 
life more so than other skin conditions such as psoriasis and atopic dermatitis. Ball et al. (2016) 
also discuss the psychosocial effects similarly to Lee et al. “Patients with hidradenitis 
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suppurativa have a mean score on the Dermatology Quality of Life Index that is higher than 
other skin conditions associated with high morbidity including eczema, acne, psoriasis and even 
chronic urticaria” (Ball, 2016, p.26). These risks show the importance of treating early and 
aggressively, it is also important because squamous cell carcinoma can develop in the regions of 
chronic inflammation.  
Theme Two: Treatment Options for Hidradenitis Suppurativa  
 Although aggressive treatment may help more serious manifestations of the disease in the 
future there are some lifestyle modifications that patients with hidradenitis suppurativa should be 
counselled on. These lifestyle modifications include smoking cessation, weigh management, and 
eating a healthy diet. Patients should also be advised to avoid wearing tight fitting clothing as 
mechanical stress or friction can increase the incidence and severity of exacerbations. of 
hidradenitis suppurativa. Other nonpharmacologic treatments include warm compresses and 
antimicrobial soap, patients should be advised to have good personal hygiene. 
 Ball et al. (2016) points out that although there is no evidence to support the use of 
topical antiseptics such as chlorhexidine lotion for hidradenitis suppurativa, it is frequently 
advised. Although there were no randomized placebo controlled studies found for antibiotic use 
for hidradenitis suppurativa in the last ten years there were discussions in several peer reviewed 
review articles regarding antibiotic use. Lee et al (2017) state in their review that topical 
clindamycin is used for more mild cases of hidradenitis suppurative if the affected areas are more 
localized. Oral antibiotics, usually a tetracycline, seem to be used when the disease is more 
widespread. Generally, treatment with oral antibiotics need to be continued for two to three 
months. “After oral antibiotic use its common to have reoccurrence of lesions” (Lee, 2017). Ball 
et al. (2016) state that if the oral tetracycline proves ineffective a more potent treatment of oral 
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clindamycin and rifampicin twice daily for three months is effective in 80% of cases. If 
antibiotics prove ineffective the next step in usually a retinoid. Ball et al. (2016) discuss that 
acitretin is more effective than isotretinoin, but because of the teratogenic risk with acitretin, 
isotretinoin is favored in younger women. Surgical treatment for HS is controversial and has not 
been studied enough to say whether it is of any benefit. For active abscesses, incision and 
drainage may be necessary. “It is beneficial in relieving acute pain and suffering, but this 
approach has been discouraged for long term practice because of the high recurrence rate” 
(Scuderi, 2017, p.102).  
 A systematic review retrieved from the Cochrane Library by Ingram et al. (2015) 
discusses all interventions for hidradenitis suppurativa. This review searched five databases, five 
trial registers, and searched conference proceedings of eight dermatology meetings for all 
randomized control trials regarding interventions for hidradenitis suppurativa. “Moderate quality 
evidence exists for adalimumab, which improves DLQI score when 40 mg is given weekly, twice 
the standard psoriasis dose. However, the 95% confidence interval includes an effect size of only 
1.5DLQI points, which may not be clinically relevant, and the safety profile of weekly dosing 
has not been fully established. Infliximab also improves quality of life, based on moderate 
quality evidence” (Ingram, 2015, p.2). “More RCTs are needed in most areas of HS care, 
particularly oral treatments and the type and timing of surgical procedures. Outcomes should be 
validated, ideally, including a minimal clinically important difference f or HS” (Ingram, 2015, 
p.2). This systematic review further supports the need for more randomized control studies, not 
only for adalimumab for hidradenitis suppurativa, but all interventions used to treat this poorly 
understood skin condition. 
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 Kerdel (2014) wrote an article discussing many different nonsurgical medications 
available for hidradenitis suppurativa. This article reviews information about antibiotics, 
corticosteroids, hormones, metformin, retinoids, and immunosuppressants for hidradenitis 
suppurativa. Many studies only focus on one type of treatment and this article summarizes 
almost all of the nonsurgical treatment options. However, it does state under each category what 
supporting evidence there is out there in the form of clinical trials to support their use and many 
of the treatment options do not have this evidence from trials to support their use. Kerdel (2014) 
discusses topical clindamycin for early treatment for hidradenitis suppurativa, and states that an 
early, small, double blind study did show significant reduction in number of abscesses, 
inflammatory nodules and pustules when compared to placebo. Kerdel (2014) also discusses the 
use of hormonal therapy such as spironolactone for hidradenitis suppurativa in women, however 
there are no studies available to support its use. Metformin which is used to treat type II diabetes 
is believed to help hidradenitis suppurativa, especially in women, however there are no available 
studies to support the use of metformin for this disorder (Kerdel, 2014). Corticosteroids are used 
intralesionally when there are active lesions and this helps settle down the inflammation and 
pain, systemic corticosteroids such as prednisone have shown beneficial when treating this 
disorder, however because of the complications that systemic corticosteroids pose with long term 
use they should not be used to treat this chronic lifelong disease (Kerdel 2014).  
Theme Three: Adalimumab for Hidradenitis Suppurativa  
 Fotiadou et al. (2016) in a review article compares different biologic agents to 
adalimumab for the treatment of hidradenitis suppurativa. Although other biologics have shown 
some promise there are just not enough clinical trials to support their use. Adalimumab by far 
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has the most support from the evidence supplied by clinical trials in the treatment of hidradenitis 
suppurativa. 
Kimbal et al. (2012) conducted a phase II, parallel, randomized, placebo-controlled trial 
consisting of a blinded 16-week period (period 1) and an open-label 36-week period (period 2). 
The study consisted of 154 adult patients with moderate to severe hidradenitis suppurativa that 
were unresponsive to oral antibiotics. This study pertains to my topic because it assesses the 
efficacy of adalimumab for HS in a group of patients that did not respond to one of the 
traditional treatments for HS. I choose this study because it had a relatively high number of 
subjects when compared to some of the other studies, I also liked how the study was blind to 
everyone involved for the first 16 weeks of the study to avoid bias. However, period 2 of the 
study was open label for 36 weeks which was a majority of the study time and knowing which 
patients were receiving the actual medication could lead to some bias opinion. Also in this study 
one group of subjects was given every other week (EOW) dose, but this group was switched to 
an every week dose if results were suboptimal. I would have preferred for the entire study to be 
blind to avoid bias, and also for each group to continue their original treatment throughout the 
entire study. At week 16, 3.9% of the placebo patients (2 of 51), 9.6% of the EOW patients (5 of 
52) and 17.6% of weekly patients (9 of 51) achieved clinical response. Serious adverse effects 
rates were 3.9% for placebo, 5.8% for EOW, and 7.8% for the weekly patients. Patient reported 
outcomes were significantly greater in the weekly dosing group when compared to the placebo 
group. When the weekly dosing group was switched to the EOW during period 2 of the study, a 
decrease in response was seen. 
Kimball et al (2016) conducted two phase three trials, PIONEER I and II followed 633 
patients with HS and the use of adalimumab. These were double-blind placebo controlled studies 
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that took course over a 36-week time period. Many other studies and review articles base their 
information from these two extensive studies. Between the two studies there were 633 patients 
which is a large patient number compared to many other studies.  The study was blind to all 
involved for the first twelve weeks and there was a placebo control for comparison. “In period I 
of each study there were significantly more patients in the adalimumab group than the placebo 
group that met the primary efficacy end point of clinical response at week 12 (PIONEER I: 
41.8% vs. 26.0%, P=0.003; PIONEER II: 58.9% vs. 27.6%, P<0.001)” (Kimball, 2016). Many of 
my other references refer to these studies in their work or are based from these studies. A review 
article by Tappenden et al. (2017) reviewed the findings of the pioneer studies and assessed the 
cost of adalimumab vs other treatment options, taking the effectiveness into consideration. 
Tappenden et al. (2017) found through their review that adalimumab is a cost-effective treatment 
for adults with hidradenitis suppurativa whose disease has not responded to conventional 
systemic therapy.  
Miller et al (2011) conducted an earlier study that was used to assess adalimumab for 
hidradenitis suppurativa treatment. This study was randomized, double-blind, and placebo-
controlled. Having the study be blind helps to eliminate bias by the subjects and the conductors 
of the study, and a placebo control group works well for comparison purposes. The study used 
primary efficacy endpoints that were changes in the Sartorius and Hurley scoring systems. The 
Sartorius scoring systems assigns numbers based on the location of lesions, number of lesions, 
distance between lesions, and dryness of the skin. The Hurley scoring system was explained 
earlier in the introduction to this paper. This study found a significant reduction of the Sartorius 
score after 6 weeks and an almost significant reduction after 12 weeks of active treatment when 
compared to the placebo group (-10.7 vs. 7.5, P=0.024 and -11.3 vs. 5.8, P=0.07). There was no 
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significant change of Hurley score seen. There were only 21 patients included in this study, 
ideally for a study like this we would like to see larger patient numbers. Hidradenitis 
Suppurativa, although not rare, is not very common and finding patients for the study in an 
accessible area would be difficult.  
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Discussion 
 Hidradenitis suppurativa is not common but it is common enough that it is seen in 
primary care clinics. This disease can be very difficult to treat and there are many factors, it is a 
disorder that should be referred to dermatology for treatment and follow through. Although there 
are some studies on adalimumab for HS there are not many good studies for many of the 
traditional treatments. This does not mean there is no place for traditional treatments when 
dealing with HS, it is multifactorial and treatment should be patient dependent. There are also 
non-pharmaceutical aspects to treatment such as weight loss, smoking cessation, and good 
control of diabetes, that are not mentioned in clinical studies as extensively as pharmaceutical 
treatments but still very important in the treatment process.  
Through the literary review I found three clinical trials and they all found that 
adalimumab had significant benefit when compared to placebo. I also found several review 
articles discussing the etiology and epidemiology of hidradenitis suppurativa, and several review 
articles discussing many of the treatment options for this disease as well.  
In patients with hidradenitis suppurativa is adalimumab more effective than traditional 
treatments to include antibiotics, hormone therapy, retinoids, corticosteroid injections, 
surgical intervention, and pain management in treatment outcomes? 
 Kimball et al. (2016) discovered in both of their phase three studies that the results at 12 
weeks confirmed that 40 mg of adalimumab weekly was efficacious for the treatment of 
moderate-to-severe hidradenitis suppurativa.  Although, the patients in this study saw significant 
improvement by week 12 with adalimumab weekly vs. placebo, the patients did not have 
complete resolution of symptoms. These PIONEER studies were the longest studies with the 
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largest patient numbers assessing adalimumab for hidradenitis suppurativa and were used when 
deciding treatment guidelines and dosing. 
 Miller et al. (2011) discovered through their study that there was a significant reduction 
in hidradenitis suppurativa severity after 6 weeks. There was an almost significant improvement 
seen at week 12. This study was very small and included only 21 patients that were followed for 
12 weeks. 
 Kimball et al. (2012) found through their study that adalimumab dosed once weekly 
alleviates moderate-to-severe hidradenitis suppurativa. In this study the patients who had the 
weekly dosing of adalimumab had significant improvement with patient reported outcomes as 
well as significant improvement in HS-PGA scores, DLQ1 scores, TWPI cores, and PHQ9 
scores. 
 These three studies all proved that adalimumab is efficacious when used to treat 
hidradenitis suppurativa. However, these studies were done compared to placebo and therefore 
do not directly measure the results of adalimumab vs the other treatment options. As I have 
stated throughout this paper, there are almost no studies available to assess the use of any of the 
traditional treatment options for hidradenitis suppurativa. With that being said, there has 
historically been very little success with traditional options and there has been some success with 
adalimumab.  
In patients with hidradenitis suppurativa does adalimumab show better treatment 
outcomes in patients with severe disease vs mild or moderate disease? 
 The three clinical trials that I used for my research have patients with moderate-to-sever 
hidradenitis suppurativa that have already failed traditional treatment options. There are no 
studies assessing adalimumab for mild hidradenitis suppurativa, I believe that this is because in 
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the mild stage of the disease some of the traditional treatment options may keep the symptoms 
dampened down enough to where the patients do not seek more complex treatment. This could 
also be because patients with a mild form of the disease or in the beginning stages, may not have 
enough discomfort to search out treatment for their condition. 
 These studies that focus on adalimumab for moderate-to-severe hidradenitis do not 
distinguish between the moderate patient’s vs the severe patients so it is uncertain whether 
adalimumab works better for one stage of the disease vs the other. However, Kimbal et al. (2012) 
did state that patients who had hidradenitis for a longer period of time generally saw better 
results. It is unknow why this is and there is no data listed to support this claim. 
In patients with hidradenitis suppurativa are the side effect outcomes associated with 
adalimumab treatment more significant and detrimental than side effect outcomes 
associated with the traditional treatment options? 
 Adalimumab is a biologic and like any medication there are side effects, some that are 
serious. Truven Health Analytics Inc. (2018) accessed from DynaMed Plus has all the adverse 
effects listed. The more common adverse effects being injection site reaction or pain, headache, 
sinusitis, and upper respiratory infection. There are many more serious side effects that are rarer 
to include cardiovascular, dermatological, gastrointestinal, hematological, hepatic, immunologic, 
musculoskeletal, neurologic, and respiratory issues. Because of all the potential side effects 
patients using adalimumab should be checked for hepatitis B and tuberculosis. Patients should 
also have liver function checked throughout treatment about every three months and be seen in 
clinic every 3-6 months which is patient dependent.  
 Kimball et al. (2016) found in their studies that adverse effects, serious adverse effects, 
infectious events, or number of patients that discontinued the study drug due to adverse effects 
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were similar between the two study group. Worsening of underlying disease was excluded from 
the rates of adverse effects. “The majority of adverse events were mild or moderate in severity” 
(Kimball, 2016, p.432). During period one the rates of adverse effects were 1.3% in the 
adalimumab group and 1.3% in the placebo group for PIONEER I, and 1.8% for the adalimumab 
group and 3.7% in the placebo group for PIONEER II. During period two the rates were 4.6% or 
less in all groups for both studies (Kimball, 2016) 
 Miller et al. (2011) state in their study that although adalimumab was well tolerated, there 
were more adverse effects seen in the adalimumab group than the placebo group with regard to 
mild infections. “However, the difference was only almost significant (P=0.16 and P=0.79, 
respectively)” (Miller, 2011, p.395). All other adverse effects were not significant in the 
adalimumab group when compared to the placebo group. This study was very short in duration 
and they do state the disadvantage of not following the patients for a longer amount of time in 
regard to adverse effects. 
 Kimball et al. (2012) assessed adverse effects, laboratory values, and vital signs 
throughout the study. In this study there were no deaths, cancer, or tuberculosis events that 
occurred (Kimball, 2012). The rates of adverse effects in the EOW and weekly adalimumab 
groups was higher than those of the placebo group (Kimball, 2012). “Fifteen patients had one or 
more serious adverse events during exposure to adalimumab, with the most common events 
being hidradenitis suppurativa worsening or infectious complications of hidradenitis suppurativa, 
and anemia” (Kimball, 2012, p.852). After the first 16 weeks of this study patients who were 
receiving the EOW dosing of adalimumab were switched to weekly dosing if they had not 
reached satisfactory results on EOW dosing. The adverse effect in this group was similar to rates 
of adverse effects in the group that had EOW dosing throughout the study. 
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Applicability to Practice and Guidelines 
 For this project, I consulted Dr. Angela Aakhus, she is a dermatologist working at 
Sanford Health in Bemidji, MN. She is a graduate from the University of Minnesota and has 
been working in Dermatology for 6 years. Currently, Dr. Aakhus has four patients she is treating 
for HS that are all using adalimumab. All four of her patients report success with this medication, 
also none of them have experienced any side effects from this medication. Dr. Aakhus states that 
in her experience the traditional treatment options for hidradenitis suppurativa provide little relief 
for patients. She states that in her practice she will start patients on adalimumab after they have 
failed topical treatments, incision and drainage with steroid injections, and oral antibiotics, if the 
patient does not have any other health concerns that would prevent them from using 
adalimumab. Even with patients on adalimumab and seeing success she discusses how incision 
and drainage with steroid injection may still be necessary for active lesions. During my time in 
my dermatology rotation I saw two hidradenitis suppurativa patients, one had more moderate-
severe disease and has been started on adalimumab 3 months ago. The other patient had more 
mild hidradenitis suppurativa and had not yet tried traditional treatments. The woman who is on 
adalimumab reports good results and her active nodule count has improved, however she did 
have an active nodule that needed incision and drainage with corticosteroid injection even when 
on the adalimumab. The woman with the milder form of the disease will start with topical 
treatments first and oral spironolactone, patient is to follow up in three months’ time. 
 Current guidelines for treating Hurley Stage I hidradenitis suppurativa were found on 
DynaMed Plus for this study and are as follows: consider antibiotics in patients with Hurley 
stage I disease and only a few flares/year, topical therapy, warm compresses, apply clindamycin 
1% lotion topically morning and evening, benzoyl peroxide wash, oral therapy - consider short 
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course (7-10 days) of oral antibiotics, including tetracyclines (doxycycline, minocycline) 
amoxicillin-clavulanate (may be most effective for acute flares) clindamycin (DynaMed Plus, 
2016). 
 For treating Hurley Stage II hidradenitis suppurativa DynaMed Plus lists the following 
for guidelines: for patients with well-controlled stage II disease, use stage I treatment regimen to 
treat flares, in patients with little scarring and severe inflammation consider clindamycin 300 mg 
twice daily plus rifampin 300 mg twice daily orally for 3 months for maintenance therapy, 
consider tetracyclines (doxycycline, minocycline) or dapsone 25-200 mg/day orally. 
 For treating Hurley Stage III hidradenitis suppurativa DynaMed Plus lists the following 
for guidelines: consider anti-inflammatory antibiotics (clindamycin plus rifampin) in patients 
refractory to antibiotics, consider immunosuppressants, tumor necrosis factor (TNF) inhibitors. 
“Adalimumab 40 mg/week associated with clinical improvement in adults with moderate-to-
severe hidradenitis suppurativa (level 2 [mid-level] evidence)” (DynaMed Plus, 2016).  
 DynaMed Plus (2016)  also mentions surgical options to include: consider surgical 
unroofing in patients with scarring and/or sinus tracts that have not progressed to advanced 
branching lesions of stage III disease for patients with Hurley stage III hidradenitis suppurativa 
refractory to medical management, consider wide excision to remove all affected tissue carbon 
dioxide (CO2) laser excision reported to reduce lesions of hidradenitis suppurativa (level 3 
[lacking direct] evidence). 
 After discussing treatment guidelines for the different stages of hidradenitis suppurativa 
DynaMed Plus then discussed each treatment in more detail and lists the recommendation score 
and level of evidence to support each treatment. Almost all of the treatment options, although 
listed by DynaMed Plus and recommended, do not have very high level of evidence to support 
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their use. This has been a reoccurrence throughout this project that there is little evidence to 
support most of the treatments.  
 The current guidelines do recommend adalimumab for moderate-to-severe hidradenitis 
suppurativa, which is supported by my research. These guidelines from DynaMed are very 
applicable to clinic use, but there is no cure and treatment is patient dependent with much trial 
and error. Hidradenitis suppurativa is difficult to treat and should not be treated in primary care, 
this should be maintained by the dermatology department. Some lifestyle modifications such as 
smoking cessation, good control of blood sugars with diabetic patients, and weight loss can be 
encouraged in a primary care setting. 
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